| Business Summary | | NeoTherapeutics,
Inc.
is
a
development-stage
biopharmaceutical
company
engaged
in
the
discovery
and
development
of
novel
therapeutic
drugs
intended
to
treat
neurological
diseases
such
as
memory
deficits
associated
with
Alzheimer's
disease
and
aging,
spinal
cord
injuries,
Parkinson's
disease
and
other
neurodegenerative
and
psychiatric
diseases.
The
Company
has
also
become
engaged
in
research
involving
functional
genomics
and
the
development
of
oncology
drugs.
The
Company's
lead
product
candidate,
Neotrofin
(AIT-082,
leteprinim
potassium),
and
other
compounds
under
development,
are
based
on
its
patented
technology.
This
technology
uses
small
synthetic
molecules
to
create
non-toxic
compounds,
intended
to
be
administered
orally
or
by
injection,
that
are
capable
of
passing
through
the
blood-brain
barrier
to
rapidly
act
upon
specific
target
cells
in
specific
locations
in
the
central
nervous
system,
including
the
brain. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NeoTherapeutics,
Inc.
is
a
development
stage
biopharmaceutical
company
engaged
in
the
discovery
and
development
of
novel
therapeutic
drugs
intended
to
treat
neurodegenerative
diseases
and
conditions.
For
the
six
months
ended
6/30/01,
revenue
totaled
$8
thousand,
up
from
$0.
Net
loss
decreased
44%
to
$12.1
million.
Revenues
reflect
a
licensing
agreement
with
Pfizer.
Lower
loss
reflects
the
termination
of
several
contracts
with
outside
clinical
R&D
groups. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Alvin Glasky, Ph.D., 67 Chairman,
CEO, & Exec. Pres of NeoGene Technologies, Inc. | $1.1M | Rajesh Shrotriya M.D., 57 Pres,
COO | 110K | Samuel Gulko, 69 CFO,
Sr. VP-Fin., Sec., Treasurer, Director | 171K | Michelle Glasky, Ph.D., 41 VP-
Scientific Affairs | 140K | F. Jacob Huff, M.D., 52 VP,
Clinical Affairs | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|